Biodesix, Inc. (BDSX) 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of Biodesix, Inc.'s 2026 Annual Meeting of Stockholders held on May 19, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "BDSX". As of the record date of March 23, 2026, there were 10,107,219 shares of common stock issued and outstanding entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders voted on four proposals, all of which were approved or ratified:
- Director Elections: Two Class III director nominees, Jean Franchi and Hany Massarany, were elected to serve until the 2029 annual meeting. Both received zero votes against.
- Executive Compensation: The compensation of named executive officers was approved on a non-binding advisory basis.
- Compensation Vote Frequency: Stockholders approved soliciting advisory votes on executive compensation on an annual (one-year) basis.
- Auditor Ratification: The appointment of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2026, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (10,107,219) and the breakdown of votes (For, Against, Abstentions, Broker Non-Votes) for each proposal.
- Confirm the tenure of the newly elected Class III directors (Jean Franchi and Hany Massarany) extending to 2029.
- Note that the frequency of executive compensation advisory votes was set to one year.
- Confirm KPMG LLP's role as the independent auditor for the fiscal year ending December 31, 2026.